Many studies on the combination of THM and conventional chemotherapy have shown synergistic effects in lung cancer.[11,13] In particular, several clinical reports have indicated that the combination of adjuvant THM and EFGR-TKI, such as gefitinib, in patients with EGFR mutation-positive advanced NSCLC has shown good results, increasing OS and PFS and reducing side effects.[12–14]. The gene discussed is EGFR; the disease is lung carcinoma.